Q: Could you review hypoadrenocorticism in young dogs?
A summary of the factual information included in our discussion of hypoadrenocorticism that follows is provided in Table 1,
p. 4S. Primary hypoadrenocorticism is most often diagnosed in young dogs -maybe as young as 8 weeks of age. Secondary hypoadrenocorticism
resulting from ACTH deficiency is relatively common in puppies afflicted with deficiencies of the pituitary gland.
 Table 1
|
Signs
The clinical signs of hypoadrenocorticism are intermittent vomiting, diarrhea, weight loss, lethargy, anorexia and weakness.
These signs often resolve with fluid therapy and/or corticosteroid treatment. Physical examination of dogs in an acute hypoadrenal
crisis shows weak pulse, bradycardia, prolonged capillary refill time, depression and severe muscle weakness. Clinical findings
of hypoadrenocorticism that heighten the index of suspicion include a normal or slow heart rate in the face of circulatory
shock and the waxing and waning course of disease prior to collapse.
Severe hyponatremia and hypochloremia associated with hyperkalemia are the hallmarks of hypoadrenocorticism. Although a serum
Na:K ratio of less than 27:1 is considered suggestive of hypoadrenocorticism, it is never pathognomonic.
Gastrointestinal disease, acute renal failure, and postrenal azotemia may also cause a low Na:K ratio. Some dogs with hypoadrenocorticism,
especially those dogs with only a glucocorticoid deficiency, will not show the typical electrolyte disturbances.
Azotemia and hyperphosphatemia are also associated with primary hypoadrenocorticism and make it difficult to differentiate
from the azotemia of acute renal failure. The hematologic abnormalities are eosinophilia and lymphocytosis or normal eosinophil
and lymphocyte counts in the face of any metabolic stress.
The anemia of hypoadrenocorticism usually results from ongoing hemorrhagic gastroenteritis and not caused by the endocrine
problem itself.
Although hypoglycemia is more commonly associated with secondary or atypical hypoadrenocorticism, it is infrequently seen
with primary hypoadrenocorticism. Urine specific gravity is frequently low and is attributed to an inadequate medullary gradient
due to sodium depletion and decreased medullary blood flow. Dilute urine along with azotemia and hyperkalemia may easily be
mistaken for acute renal failure.
Diagnosis of primary hypoadrenocorticism is based on clinical signs, expected electrolyte disturbances and confirmation with
an ACTH stimulation test. The technique used for performing the ACTH stimulation test includes:
- Baseline cortisol sample should be collected with the initial blood work and synthetic ACTH should be administered intravenously
during the initial fluid therapy.
- 2. One-hour after ACTH administration, a second cortisol sample is collected and a glucocorticoid is then administered in
the suspected dog with hypoadrenocorticism. Intramuscular injection of synthetic or gel ACTH may not be absorbed in dogs in
circulatory shock; thus, intravenous administration of synthetic ACTH is preferred.
 Table 1 Continued
|
If glucocorticoids must be administered before cortisol is measured, dexamethasone sodium phosphate is used because dexamethasone
will not interfere with the cortisol assay used in the diagnostic laboratory.
ACTH
Endogenous plasma ACTH may be measured to determine if the hypoadrenocorticism is primary or secondary. This specimen must
be collected in an EDTA tube, spun within one hour of sampling and stored in a plastic container before corticosteroids are
administered.
Dogs with primary hypoadrenocorticism will exhibit a subnormal response to ACTH administration. The baseline cortisol concentration
is usually low or undetectable and the post-ACTH cortisol concentration is also low or undetectable.
Endogenous plasma ACTH concentrations are dramatically increased in animals with primary hypoadrenocorticism as a result of
loss of negative feedback to the pituitary gland caused by decreased serum cortisol concentrations.
In the case of secondary hypoadrenocorticism, which is caused by a pituitary deficiency of ACTH, the endogenous ACTH concentrations
are usually decreased (<20 pg/ml). The response to exogenous ACTH is diminished, but not as dramatically as for primary hypoadrenocorticism.
Baseline cortisol and post-ACTH cortisol concentrations may be in the normal range.
Options for treatment
Treatment of the Addisonian crisis includes:
- fluid therapy for electrolyte stabilization.
- glucocorticoid replacement therapy.
- treatment of gastrointestinal disease.
- and mineralocorticoid replacement therapy.
Normal saline solution without potassium supplementation is the preferred fluid solution for the hypoadrenal crises.
Treatment of hyperkalemia can be achieved using fluid therapy alone. If hyperkalemia is life threatening, intravenous administration
of calcium chloride or calcium gluconate may be used to counteract the adverse effects of potassium on the heart.
Glucocorticoid and mineralocorticoid therapy must be initiated after diagnostic tests for hypoadrenocorticism have been performed.
Glucocorticoid therapy, using ultra-short acting corticosteroids such as dexamethasone sodium phosphate and prednisolone sodium
succinate, is indicated. Dexamethasone may be preferred in some dogs that require immediate glucocorticoid administration,
as it will not interfere with the cortisol assay; in addition, a single dose of short-acting corticosteroid will not suppress
the hypothalamic pituitary adrenal axis.
Fludrocortisone
Long-term therapy of primary hypoadrenocorticism involves the use of mineralocorticoid supplementation as oral fludrocortisone
(0.1 mg per 10 lb orally every 24 hours) or injectable deoxycorticosterone pivalate (2 mg/kg every 21-30 days).
Electrolytes should be monitored once weekly until the dog is stable on replacement therapy. Most dogs with secondary hypoadrenocorticism
and those supplemented with deoxycorticosterone pivalate require a low dose of glucocorticoids (0.2 mg/kg orally every 24
hours). About 50 percent of Addisonian cases supplemented with fludrocortisone require glucocorticoid supplementation.